Background Increasing evidence suggests that seizures and status epilepticus can be immune-mediated. We aimed to describe the clinical features of a new epileptic disorder, and to establish the target antigen and the eff ects of patients' antibodies on neuronal cultures.
Introduction
Seizures and status epilepticus can result from immunological responses to excitatory or inhibitory synaptic receptors or associated cell-surface proteins. [1] [2] [3] These include the N-methyl-D-aspartate receptor (NMDAR), 4 the alpha-amino-3-hydroxy-5-methyl-4-isoxazole pro pionic acid receptor (AMPAR), 5 the gamma-aminobutyric acid-B receptor (GABA B R), 6 leucine-rich glioma inactivated protein 1 (LGI1), 7 contactin-associated protein-like 2 (Caspr2), 8, 9 dipeptidyl-peptidase-like protein-6 (DPPX), 10 and the metabotropic glutamate receptor 5 (mGluR5).
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The seizures that accompany any of these disorders are often refractory to antiepileptic treatment unless the immune mechanism is identifi ed and treated. 6, 12, 13 In some patients, generalised seizures or status epilepticus can be the fi rst manifestation of the disease, with patients needing heavy sedation or induced pharmacological coma. 6, [14] [15] [16] These treatments might conceal other symptoms such as dyskinesias or psychiatric alterations, delaying the recognition of the syndrome. Hitherto, the main epilepsy-related inhibitory receptor known to be a target of autoimmunity was the GABA B R. 9, 16, 17 Most patients with GABA B R antibodies develop early seizures or status epilepticus as a component of limbic encephalitis. About 50% of these patients have an underlying small-cell lung cancer, and the neurological symptoms usually respond to immunotherapy and treatment of the cancer. 9, 16, 17 Although the GABA B R belongs to the category of metabotropic G protein-coupled receptors, the GABA A receptor (GABA A R) is a ligand-gated ion channel that modulates most of the fast inhibitory synaptic transmission in the brain and has not been previously recognised as a target of autoimmunity.
The identifi cation of the above-mentioned disorders, all potentially treatable with immunotherapy, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] has enhanced aware ness of autoimmune mechanisms in patients with encephalitis associated with refractory seizures or status epilepticus, leading to an increased recognition of cases in which the antigens are unknown. Some patients might have several autoantibodies, suggesting that they have a propensity to autoimmunity, but also leading investigators to attribute the disorder to intracellular antigens that are not accessible to circulating antibodies, such as thyroid peroxidase or glutamic acid decarboxylase 65 (GAD65), 5, 6 and therefore of questionable pathogenic signifi cance. In such patients, other more relevant, yet unknown cellsurface antigens can be overlooked, as occurred in previously reported patients who were eventually shown to have AMPAR or GABA B R anti bodies. 5, 6 We aimed to establish the identity of a novel synaptic antigen in a subset of patients with encephalitis and refractory seizures or status epilepticus. We report the clinical features of this new syndrome, the identity of the antigen, and the eff ects of patients' antibodies on neuronal cultures.
Methods

Study design and participants
Between Aug 20, 2012 , and Dec 10, 2012, we identifi ed two patients with encephalitis, refractory seizures, and serum and CSF antibodies with a similar pattern of reactivity against the neuropil of rat brain (appendix). The severity of the symptoms and unknown identity of the antigen prompted us to immuno precipitate the antigen and to retrospectively review clinical and immunological information from patients with similar symptoms. We assessed serum and CSF samples, collected worldwide between April 28, 2006, and April 25, 2013 , from 1134 patients with encephalitis and seizures that were suspected to be autoimmune. The samples had been sent to two referral centres (Department of Neurology, Hospital of the University of Pennsylvania, PA, USA, and Center of Neuro immunology, Institut d'Investigacions Biomediques August Pi i Sunyer [IDIBAPS] , Hospital Clinic, University of Barcelona, Barcelona, Spain) for confi rmation of the presence of cell-surface antibodies or investigation for novel antibodies after standard laboratory studies were negative. Serum and CSF samples were kept frozen at -80º C. For all patients, we obtained clinical information using a questionnaire completed by the treating physicians when the samples were sent to our centres. The treating physician also did subsequent clinical follow-up via email or phone.
Of these 1134 patients, 356 (44%) had antibodies that reacted with known cell-surface or synaptic antigens such as NMDAR, AMPAR, and LGI1, and 140 (including the two index patients) had the triad of encephalitis, seizures, and antibodies against unknown rat brain neuropil antigens. In all instances, the assessment of antibodies to brain neuropil antigens was done independently by two investigators (FG and JD), with results kept in a database. We then re-examined serum and CSF samples from these 140 patients with immunohistochemistry of rat brain, cultured live neurons, and a cell-based assay to establish whether they had similar antibodies to the two index patients. We also examined serum samples from 75 otherwise healthy individuals (blood donors) and serum or CSF samples from 416 patients with a range of neurological disorders (worldwide referrals). These 416 patients with diverse disorders were re-examined for neuropil antibodies and antibodies to α1/β3 subunits of the GABA A R. They included 41 seronegative patients with encephalitis and seizures or status epilepticus, 59 with opsoclonusmyoclonus, 20 with non-infl ammatory degenerative ataxia, nine with herpes-simplex-virus encephalitis, 30 with multiple sclerosis, 101 with antibodies against GAD65 (16 limbic encephalitis, 33 epilepsy, 13 ataxia, 39 stiffperson syndrome), 90 with stiff -person syndrome without GAD65 antibodies, 30 with NMDAR antibodies, 19 with GABA B R antibodies, and 17 with LGI1 antibodies. Only serum samples were available from 238 patients, and only CSF samples were available from 35 patients, with both types of samples available from 143 patients.
Partial clinical information about two patients with coexisting GABA B R antibodies (patients 4 and 6) has been reported elsewhere. 9, 18 Our fi nal protocol was approved by the institutional review boards of the University of Pennsylvania and the Hospital Clinic, and written informed consent was obtained from all patients or representatives.
Laboratory procedures
All laboratory techniques are described in the appendix and elsewhere. 5, [19] [20] [21] [22] Briefl y, we did immuno histochemistry on rodent brain, immuno cytochemistry of rodent neuronal cultures, immuno precipitation, mass spectrometry, immuno absorption and immune-competition studies, immuno cyto chemistry on live or fi xed HEK293 cells (cellbased assays), quantitative analysis of neuronal GABA A R immunoreactivity of patients' antibodies, and analysis of the eff ects of these antibodies on GABA A R using confocal microscopy.
Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
On immunohistochemistry with rat brain, the serum and CSF samples of the two index patients produced a similar and intense pattern of neuropil reactivity (fi gure 1, appendix). This neuropil reactivity resembled that reported for GABA B R antibodies (fi gure 1, appendix), 6 but specifi c testing for these antibodies with a cell-based assay was negative in both index patients (data not shown). Findings from a subsequent assessment with cultured live rodent hippocampal neurons showed that the novel antigen was on the cell surface (fi gure 1). Immunoprecipitation of neuronal proteins reacting with antibodies from the two index patients, followed by electrophoretic protein separation and EZBlue gel staining, did not produce any specifi c band compared with serum samples from individuals in the healthy control group (data not shown). Mass spectrometry of all separated proteins showed that serum samples from the two index patients but not from otherwise healthy control individuals had precipitated protein fragments containing sequences of the β3 subunit of the GABA A R (sequences shown in appendix).
Because the β3 subunit of the GABA A R forms complexes with the α1 subunit, we tested the reactivity of patients' antibodies with HEK293 cells transfected with the human α1 or β3 subunits or both. This cell-based assay identifi ed GABA A R antibodies in six patients, including four of the 140 patients with encephalitis, seizures or status epilepticus, and antibodies to unknown neuropil antigens, and two of the 19 patients with GABA B R antibodies. All six patients' serum and CSF samples reacted with cells coexpressing α1 and β3 subunits, but when the subunits were individually assessed, four patients' samples reacted with both the α1 and β3 subunit, one patient's sample reacted with only the α1 subunit, and another patient's sample reacted with only the coexpression of α1 and β3 subunits. For this reason, we subsequently used α1 and β3 heteromers to assess antibody titres. To optimise the cell-based assay, we compared the sensitivity of the assay with live or fi xed and permeabilised α1/β3 receptor-expressing HEK293 cells (live cell-based assay vs fi xed cell-based assay). These studies showed that all patients' CSF antibodies were detectable with either live or fi xed cell-based assay, but serum antibodies were mostly visible with live cell-based assay (fi gure 2).
Immunocompetition assays with serum antibodies of the six patients showed that all recognised the same epitopes of the GABA A R (appendix). Immunoabsorption of a representative serum sample with HEK293 cells expressing the α1/β3 subunits resulted in abrogation of reactivity in rat brain and culture neurons, further confi rming the reactivity with the GABA A R (fi gure 3).
Using live cell-based assay in cells coexpressing α1/β3, we identifi ed two clinical-immunological groups of patients: the fi rst comprised the six patients with GABA A R antibodies identifi ed from the cohort of 140 patients with encephalitis and unknown neuropil antigens and from the group of 19 patients with GABA B R antibodies; all six patients had a high titre (>1:160) of serum (when available) and CSF GABA A R antibodies (patients 1-6; table. The second group consisted of 12 patients from the disease control groups, but not from the group of healthy individuals. In these 12 patients, the serum antibody titre was always 1:160 or lower; CSF samples were available from three individuals (patients 7, 12, and 18) and all three were negative. Moreover, whereas in patients in the fi rst group the antibodies were detectable with three techniques (immuno histochemistry with rat brain, cultured neurons, and live or fi xed cell-based assay), in patients of the second group the antibodies were . This pattern of brain and cerebellar staining is similar to that produced by the CSF of a patient with GABA B R antibodies (C). However, patient 2 was negative for GABA B R antibodies in a specifi c cell-based assay (data not shown). These fi ndings suggested the presence of antibodies against a novel neuronal cell-surface antigen, which was confi rmed in cultures of live rat hippocampal neurons (B). The CSF of the patient with GABA B R antibodies also reacted with the neuronal cell surface, as expected (D). E and F show a similar study using CSF of a control patient without neuronal cell-surface antibodies. In B, D, and F the nucleus of the neurons was counterstained with DAPI. In A, C, and E the tissue was counterstained with haematoxylin.
detectable only with live cell-based assay (all individuals) and cultured live neurons (patients 7-13).
Five of the six patients with high concentrations of GABA A R antibodies in serum and CSF samples were male; three were children and three were adults (age range 3-63 years). All developed a rapidly progressive encephalopathy that eventually resulted in refractory seizures, fi ve of the six had status epilepticus and one of them (patient 2) also had epilepsia partialis continua (table) . In all six patients, epileptic symptoms were preceded or associated with a change in behaviour or level of cognition. A 3-year-old child (patient 4), who also had GABA B R antibodies, developed seizures along with confusion, opsoclonus, ataxia, and chorea. Another patient (patient 5) developed a progressive hemiparesis before seizures. One patient had normal CSF white-cell count and protein con centration and the other fi ve had at least one abnormality, including pleocytosis in four of six patients, increased protein concentration in four of six patients, and oligoclonal bands in two of patients (patients 2 and 6 in the table). All six patients had abnormal brain MRI, often showing extensive abnormalities on FLAIR and T2 imaging, with multifocal or diff use cortical involvement without contrast enhancement (fi gures 4 and 5); one patient had involvement of the basal ganglia. The EEG showed seizures in all patients, two of whom had periodic generalised discharges (appendix). In addition to GABA A R antibodies, three patients had thyroid peroxidase antibodies, one had GAD65 antibodies, and two had GABA B R antibodies. Other fi ndings suggestive of a propensity to autoimmunity or immune dys regulation included a past history of Hodgkin's lymphoma in one patient, and idiopathic thrombocytopenic purpura in another.
Treatment and follow-up were assessable in all six patients: one child received levetiracetam without immunotherapy and had substantial recovery, although 3 years after symptom onset he still requires antiepileptic treatment to avoid seizure recurrence. The other fi ve received immuno therapy and multiple antiepileptic drugs, and four patients needed a pharmacologically induced coma. Three of these patients had total or partial recovery and two died as a result of sepsis during status epilepticus. One death was a child (patient 4) with concomitant GABA B R antibodies indicated above (clinical and autopsy fi ndings have been reported in detail elsewhere; 18 the GABA A R antibodies were identifi ed in archived serum and CSF samples). The oldest of the six patients (age 63 years) also had GABA B R antibodies; the GABA A R antibodies were identifi ed in samples that had been archived for 7 years. This patient fully recovered from the encephalopathy associated with antibodies against both GABARs, but 7 years later developed diplopia and hemiataxia with GAD65 antibodies (without antibodies to GABARs) from which he fully recovered.
12 patients (age 2-74 years, median 26 · 5 years; seven male patients) had low serum concentrations of GABA A R antibodies (table) . Briefl y, all six patients with encephalitis had seizures; one of them (patient 7; a 2-year-old boy) with refractory status epilepticus that needed a pharmacologically induced coma, and another patient (patient 8; a 41-year-old man) with epilepsia partialis continua. In the other six patients, four had stiff -person syndrome (one of them associated with seizures), and two had opsoclonus-myoclonus. Six of the 12 patients had other neuronal antibodies in addition to GABA A R antibodies: fi ve had GAD65 and one had NMDAR antibodies. Additional fi ndings suggestive of a propensity to autoimmunity or immunological dysfunction included: Hashimoto's thyroiditis with thyroid peroxidase antibodies in one patient, and type 1 diabetes mellitus in two patients. None of the patients with stiff -person syndrome had amphiphysin or glycine receptor (GlyR) antibodies. Treatment and follow-up were assessable in nine patients. Immunotherapy was used in seven patients: one had full recovery, fi ve had partial recovery, and one died. The two patients who did not receive immuno therapy had stiffperson syndrome that was controlled symptomatically with clonazepam or baclofen.
We did the following studies with CSF of a representative patient (index patient 1) with high titre serum and CSF antibodies reacting with only GABA A R. The reactivity was abrogated by pre-absorption with HEK293 cells expressing GABA A R (fi gure 3), and by immuno competition assays with antibodies from the other fi ve patients with high antibody titres, indicating that all patients' antibodies targeted the same GABA A R epitopes (appendix). To examine the extent of recognition of GABA A R by patients' CSF antibodies, we quantifi ed GABA A R immunelabelling by confocal microscopy (fi gure 6). These results showed that 89% of patient's antibodies labelled GABA A R-containing clusters (fi gure 6). To examine the eff ects of the antibodies on inhibitory synapses containing GABA A R, neurons were treated with patient's CSF antibodies or a control CSF for 48 h. These studies showed that the density of GABA A R clusters along dendrites was not aff ected (fi gure 6), but the clusters of GABA A R at synapses, measured as cluster density co-labelled by the presynaptic marker vGAT (vesicular GABA transporter), were substantially reduced (fi gure 6). This fi nding suggests that the antibodies in the patient's CSF, but not control CSF, removed GABA A R from synapses. The eff ect was specifi c for GABA A R because the cluster density of other synaptic markers such as gephyrin (fi gure 6) and the GluN1 subunit of the NMDAR (data not shown) were not aff ected.
Discussion
We report the identifi cation of high titre serum and CSF antibodies against the GABA A R in a subset of patients with encephalitis and refractory seizures or status epilepticus, who often needed pharmacologically induced coma. This fi nding is important because the disorder is potentially treatable. However, because of the rapid development of seizures and frequent presence of coexisting autoimmune disorders, recognition of the disorder might be diffi cult. Findings from the four following sets of experiments establish GABA A R as a relevant autoantigen: direct immunoprecipitation of the receptor by patients' antibodies, specifi c immunostaining of HEK293 cells expressing α1/β3 subunits of the receptor, competition of patients' antibodies for the same GABA A R epitopes, and demonstration that patients' antibodies selectively remove GABA A R from synapses without aff ecting NMDAR or gephyrin (a scaff old protein that anchors the receptor at post-synaptic sites). Most fast inhibitory neurotransmission in the adult brain is mediated by ligand-gated GABA A R. 23 These receptors are regulated by many positive (barbiturates, benzodiazepines) and negative (picrotoxin, bicuculline) allosteric modulators, providing several models of GABA A R-antagonist induced seizures. 24, 25 The GABA A Rs are pentamers, the fi ve subunits of which originate from eight gene families that encode diff erent isoforms ((α1-6,  β1-3, γ1-3, δ, ε, , π, and 1-3) . The subunit composition of the receptor governs the intrinsic properties of the channel, such as affi nity for GABA, receptor conductance, kinetics, and modulation. 26 These 19 subunits combine in diff erent ways to form functional receptors, but at synaptic sites most receptors contain two α subunits (α1-3 isoforms), two β subunits, and a γ subunit arranged in the order γ-β-α-β-α. By contrast with receptors at synaptic sites, those at perisynaptic or extrasynaptic sites are mainly composed of α4 or α6 subunits combined with β and δ subunits. 27 The antibodies of our patients reacted with the α1, β3, or both subunits (we did not assess other subunits), and when the reactivity with each subunit was individually assessed, the α1 subunit was always recognised by patients' CSF. Therefore, that the main eff ects of patients' antibodies occurred at synaptic sites, where the α1 receptors are enriched, is not surprising. Indeed, using cultures of rat hippocampal neurons, patients' antibodies caused a decrease in the density of GABA A R at synaptic sites. The total density of GABA A Rs, including synaptic and extrasynaptic receptors, was not aff ected, suggesting a relocation of receptors from synaptic to extrasynaptic sites. This fi nding contrasts with the eff ects of antibodies identifi ed in other autoimmune encephalitis, such as anti-NMDAR or anti-AMPAR, in which the decrease of the cor responding receptors occurs at both synaptic and extrasynaptic sites. 5, 22, 28 At least four mutations in the α1 subunit of the GABA A R are associated with generalised epilepsy. 27 Findings from in-vitro studies have shown that each of these mutations results in a substantial loss of α1-subunit function or level of expression. 27 Additionally, mutations of the β3 subunit have been reported in children with absence epilepsy. 29 In line with these fi ndings, in our study, all patients with high titres of serum and CSF α1/β3 receptor antibodies developed seizures, status epilepticus, or epilepsia partialis continua. Most of these patients had an abnormal EEG with multifocal seizures and, in two cases, generalised periodic discharges. These fi ndings were associated with extensive cortical and subcortical brain MRI abnormalities in all six patients with high serum antibody titres (all with CSF antibodies) and in three (25%) of 12 patients with low serum titres. We do not know if the MRI fi ndings were caused by the immune response or resulted from the lengthy seizures. However, the multifocal and extensive brain MRI abnormalities were diff erent from those seen in other autoimmune encephalitis, in which the MRI is often normal (NMDAR) 30 or shows predominant involvement of the hippocampus (AMPAR, GABA B R, LGI1). 5, 7, 16 The comparison with other autoimmune encephalitis shows other diff erences: 39% of patients with GABA A R antibodies are younger than 18 years, whereas most patients with other encephalitis (except anti-NMDAR) are adults. 31 Patients with GABA A R antibodies do not seem to frequently have an underlying tumour (similar to LGI1 autoimmunity), whereas about 30-60% of patients with other antibodies (Caspr2, GABA B R, or AMPAR) have a tumour 32 and, for patients with NMDAR antibodies, the frequency of tumours varies with age, sex, and ethnicity. 30 Since the end of this study, we have identifi ed a patient with a malignant thymoma and encephalitis, seizures, multifocal cortical FLAIR MRI abnormalities, and LGI1 and GABA A R antibodies, suggesting that patients with thymoma and seizures should be tested for GABA A R antibodies (data not shown).
In the group with low serum titres of antibodies and absent CSF antibodies, all patients with encephalitis developed seizures; the youngest patient, a 2-year-old child, also required pharmacologically induced coma for status epilepticus. The frequent presence of other relevant autoimmunities could explain the broader spectrum of symptoms in this group. Indeed, two of the four patients with stiff -person syndrome had coexisting GAD65 antibodies, and another patient with GABA A R antibodies only detected in serum had high titres of NMDAR antibodies in serum and CSF samples that were responsible for most of the clinical features (anti-NMDAR encephalitis).
Findings from this and previous studies suggest that patients with encephalitis or seizures attributed to GAD65 antibodies should be examined for other relevant antibodies against cell-surface antigens, such as GABA A Rs and other synaptic receptors (panel). 6, [33] [34] [35] Additionally, the increasing recognition of autoimmune encephalitis with neuronal cell-surface antibodies and concurrent thyroid peroxidase antibodies (as in four of 18 patients in this study) suggests that Hashimoto's encephalitis should be a diagnosis of exclusion-that is, the detection of thyroid peroxidase antibodies and symptom response to steroids are not suffi cient criteria to establish the diagnosis of Hashimoto's encephalitis. 9, 35, 36 Evidence suggests that status epilepticus can lead to chronic epilepsy. The development of epilepsy is usually preceded by a silent period during which there is increasing hyperexcitability and a progressive decrease of synaptic GABA A R. 26 This eff ect has been attributed in part to a disruption of the GABA A R-anchoring protein, gephyrin. 26, 37 Additionally, lengthy seizures reduce GABA A R inhibition, which might lead to the development of status epilepticus. 38 These fi ndings and the antibody-mediated decrease of synaptic GABA A R seen in neuronal cultures exposed to patients' antibodies suggest a model whereby the GABA A Rs are removed from synapses leading to status epilepticus, which in turn causes a further decrease of receptors along with reduced GABA A R inhibition, resulting in a pathogenic reinforcement. This would explain the severity and refractory nature of the seizures associated with high concentrations of GABA A R antibodies, and why this disorder seems to be more diffi cult to treat than the syndromes associated with NMDAR, GABA B R, AMPAR, or LGI1 antibodies, emphasising the importance of prompt diagnosis and treatment. Despite the diffi culties in treatment, 12 of 15 patients had partial or complete response to immunotherapy (nine patients), symptomatic therapy (three patients), and extended intensive care support (all patients with encephalitis). Our study has several limitations, including the retrospective assessment of most patients (except the two index patients), and the absence of CSF samples from nine of the 12 patients with low serum titres of GABA A R antibodies. Therefore, the clinical implications of low serum antibody titres should be interpreted with caution, especially because in some patients (eg, the patients with NMDAR antibodies) other coexisting immunological mechanisms could have contributed to the patients' symptoms. Future studies should establish, in a prospective manner, the incidence of serum and CSF Live 14-day-in-vitro cultures of dissociated rat hippocampal neurons were stained with patient's CSF containing GABA A R antibodies (green), then fi xed and stained with commercial GABA A R antibodies (red; A). Quantifi cation of colocalisation between patient's CSF antibodies and the commercial GABA A R antibody shows that 89% (SE 3%) of receptors labelled by patient's antibodies were colabelled with the commercial antibody against GABA A R (B). In a similar assay, neurons were incubated with patient's CSF for 48 h and subsequently stained for postsynaptic GABA A R (green) and presynaptic vesicular GABA transporter (vGAT) (red; C). The synaptic GABA A Rs (shown as yellow clusters in control conditions) were greatly reduced after treatment with patient's CSF (C). The number of GABA A R clusters along dendrites of neurons treated with patient's CSF is not diff erent from neurons treated with control CSF (Mann-Whitney test p=0·6; D). The number of GABA A Rs localised in synapses, however, decreased signifi cantly in neurons treated with a patient's CSF compared with neurons treated with control CSF (40% [3%] compared with control as 100%; p<0·0001; E). Patients' CSF did not aff ect the clusters of post-synaptic gephyrin colabelled with presynaptic vGAT when compared with the eff ects of control CSF (p=0·5; F).
GABA A R antibodies in patients with seizures or status epilepticus, opsoclonus-myoclonus, and stiff -person syndrome with or without GAD65 autoimmunity, and whether the presence of antibodies in CSF always associates with seizures or status epilepticus.
Findings from this study have several clinical implications. The presence of GABA A R antibodies should be tested in patients with severe seizures or status epilepticus in the context of encephalitis of unclear cause with MRI and CSF abnormalities suggestive of an infl ammatory process, patients with opsoclonusmyoclonus or stiff -person syndrome, and any patients with GAD65 or thyroid peroxidase antibodies and other clinical features suggesting a propensity to autoimmunity.
In addition to the clinical implications, the identifi cation of a disorder in which patients' antibodies specifi cally eliminate GABA A Rs from synapses provides a useful reagent (purifi ed patients' antibodies) to understand how selective disruption of these receptors leads to neuronal hyperexcitability, seizures, or status epilepticus.
Contributors M-PP, TA, and XP did the literature search, study design, data collection, data analysis, writing, and critical approval of the fi nal paper. LB, TC, RD, LM, WM, MK, DR, WG, BM, CA, PSS, and MJT did the data collection and critical approval of the fi nal paper. EM-H did the data collection, data analysis, interpretation, and critical approval of the paper. RBG did the data interpretation, critical approval of the fi nal paper, and obtained funding. FG did the data collection, data analysis, data interpretation, critical approval of the fi nal manuscript, and obtained funding. JD did the fi gures, study design, data collection, data analysis, data interpretation, writing, critical approval of the fi nal paper, and obtained funding.
Confl icts of interest
JD holds patents for the use of Ma2 and NMDAR as autoantibody tests, and has fi led patents for the use of DPPX, GABA A R, and GABA B R as diagnostic tests. JD and PS-S receive research grant support from Euroimmun. PS-S has fi led a patent for the use of DNER as diagnostic test. MJT received a travel grant for Lecturing in India from Sun Pharma, India. The rest of the authors have no confl icts of interest.
